An antidandruff shampoo formulation (product code: VB-3222) consisting of a synthetic medium chain fatty acid derivative and zinc pyrithione was highly tolerable and effective for reducing scalp flaking and itching in a study of patients with moderate dandruff. Findings from this study were published in Clinical, Cosmetic and Investigational Dermatology.
A total of 25 healthy people with moderate dandruff on the scalp were enrolled in the open-label, single-group study. After a 2-week wash-in period, participants were asked to use the VB-3222 shampoo 3 times a week during the 21-day study. A 0- to 10-point scale was used to calculate the adherent scalp flaking score (ASFS) in 8 zones of the scalp for each participant, with a score of 10 representing heavy flaking. In addition, the Investigator’s Global Assessment for pruritus score was calculated, with a maximum score of 3 representing extreme discomfort.
In all in vitro cases, the VB-3222 shampoo formulation performed significantly better than marketed competitors, including a product that contained both zinc pyrithione and ketoconazole, in its fungicidal activity (P <.001). In the participants, the VB-3222 shampoo was well tolerated throughout the study.
Approximately 86% of participants had improvement in the ASFS by day 5, whereas all participants had improvements by day 7 onward. On day 9, mean adherent dandruff level reached a negligible score. At day 5 and days 9 to 16, there was also a 50% and a 95.5% reduction in the pruritus score, respectively.
Study limitations included its single-group design, the small sample size, and its exploratory nature.
The researchers concluded that the “potentiated ZPT shampoo, VB-3222, provides an effective, safe and sensorial attractive formulation for treatment of moderate adherent dandruff ensuring strong compliance.”
Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
Sadhasivam S, Garkhal K, Singh H, et al. Newly developed anti-dandruff regimen, VB-3222, delivers enhanced sensorial and effective therapeutic benefits against moderate adherent dandruff. Clin Cosmet Investig Dermatol. 2020;13:187-195.